Shikari® (Q-EVO) Evolocumab ELISA
EVO-FD-REP
Enzyme immunoassay for the quantitative determination of Evolocumab (Repatha®) in serum and plasma.
This kit has been especially developed for the quantitative determination of evolocumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Evolucumab Drug Bank Accession Number isDB09303.
Evolocumab is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. Evolocumab is a human IgG2 monoclonal antibody that targets the proprotein convertase subtilisin/kexin type 9 (PCSK9). Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 10 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 6 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
